30th Jul 2010 09:24
BTG plc: Appointment of Non-executive Director
London, UK, 30 July 2010: BTG plc (LSE: BGC), the specialty pharmaceuticals company, today announces that Ian F R Much has joined the Board as a non-executive director, effective from 1 August 2010.
Ian Much is currently a non-executive director and the senior independent director of Chemring Group PLC and of Senior plc. Ian was chief executive of De La Rue plc between 1998 and 2004 and chief executive of T&N plc between 1996 and 1998. Previous non-executive director appointments include Manchester United plc, Camelot plc and Admiral plc.
Dr John Brown, BTG's chairman, commented: "I am delighted to welcome Ian to the Board. His significant international business experience will be of great benefit to BTG as we continue to develop BTG as a commercially focused specialty pharmaceuticals company."
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Services Authority Listing Rules.
For further information contact:
|
BTG |
Financial Dynamics |
|
Andy Burrows, Director of Investor Relations+44 (0)20 7575 1741; mobile: +44 (0)7990 530605Rolf Soderstrom, Chief Financial Officer+44 (0)20 7575 0000 |
Ben Atwell+44 (0)20 7831 3113 |
About BTG
BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products. For further information, visit: www.btgplc.com.
Related Shares:
BTG